ESR1 and breast carcinoma: The current standard adjuvant treatments for patients with ERα+ breast cancer either inhibit ERα activity, e.g., tamoxifen (TAM) for premenopausal women, or block the conversion of androgens to estrogens by aromatase inhibitors (AIs), e.g., letrozole, in postmenopausal women2.